Oraxol is an oral formulation of Paclitaxel. Today only intravenous versions of Paclitaxel are available on the market to treat breast, lung, ovarian and pancreatic cancer. We have demonstrated through numerous clinical studies, that Paclitaxel is systemically absorbed by the patient through the application of our oral delivery system.
Pharmacokinetic data have shown we can achieve greater levels of Paclitaxel in the patient’s blood, as compared to today’s standard of care. We have numerous late stage Oraxol clinical trials underway and planned.